Alla Polotskaia, Sandy Hoffman, Nancy L Krett, Mala Shanmugam, Steven T Rosen, Jill Bargonetti
8-Amino-adenosine (8-NH(2)-Ado) is a ribose sugar nucleoside analogue that reduces cellular ATP levels and inhibits mRNA synthesis. Estrogen receptor-negative (ER-) metastatic breast cancers often contain mutant p53; therefore, we asked if 8-NH(2)-Ado could kill breast cancer cells without activating the p53-pathway. Regardless of the breast cancer subtype tested or the p53 status of the cells, 8-NH(2)-Ado was more cytotoxic than either gemcitabine or etoposide. 8-NH(2)-Ado treatment inhibited cell proliferation, activated cell death, and did not activate transcription of the p53 target gene p21 or increase protein levels of either p53 or p21. This occurred in the estrogen receptor-positive (ER+) MCF-7 cells that express wild-type p53, the ER+ T47-D cells that express mutant p53, and the ER- MDA-MB-468 cells or MDA-MB-231 cells that both express mutant p53. 8-NH(2)-Ado induced apoptotic death of MCF-7 cells and apoptosis was not inhibited by knockdown of functional p53. Moreover, the pan-caspase inhibitor Z-VAD blocked the 8-NH(2)-Ado-induced MCF-7 cell death. Interestingly, 8-NH(2)-Ado caused the MDA-MB-231 cells to detach from the plate with only limited evidence of apoptotic cell death markers and the cell death was not inhibited by Z-VAD. Inhibition of MDA-MB-231 cell autophagy, by reduction of ATG7 or 3-methyladenine treatment, did not block this 8-NH(2)-Ado-mediated cytotoxicity. Importantly 8-NH(2)-Ado was highly cytotoxic to triple-negative breast cancer cells and worked through a pathway that did not require wild-type p53 for cytoxicity. Therefore, 8-NH(2)-Ado should be considered for the treatment of triple-negative breast cancers that are chemotherapy resistant.
BMC Pharmacol. 2011 Jul 19;11:7
[PMID:
21771338]
Nature. 2006 Sep 14;443(7108):214-7
[PMID:
16957739]
Breast Cancer Res Treat. 2010 Jun;121(2):355-64
[PMID:
19641990]
Nat Rev Mol Cell Biol. 2007 Apr;8(4):275-83
[PMID:
17380161]
Nature. 1989 Dec 7;342(6250):705-8
[PMID:
2531845]
Mol Biol Cell. 2011 Jan 15;22(2):165-78
[PMID:
21119005]
Nat Rev Mol Cell Biol. 2008 Dec;9(12):1004-10
[PMID:
18971948]
Development. 2008 Aug;135(14):2347-60
[PMID:
18567846]
ACS Chem Biol. 2007 Jun 15;2(6):399-407
[PMID:
17530733]
Cell Death Differ. 2010 Jan;17(1):93-102
[PMID:
19498444]
Cancer Cell. 2006 Dec;10(6):515-27
[PMID:
17157791]
Endocr Relat Cancer. 2006 Jun;13(2):293-325
[PMID:
16728565]
Autophagy. 2006 Apr-Jun;2(2):85-90
[PMID:
16874083]
FEBS Lett. 2010 Apr 2;584(7):1427-35
[PMID:
20035753]
Mol Cancer Ther. 2004 Nov;3(11):1411-20
[PMID:
15542780]
Biochem Pharmacol. 2010 Mar 1;79(5):669-77
[PMID:
19814999]
Autophagy. 2010 Feb;6(2):248-55
[PMID:
20083906]
Autophagy. 2008 Feb;4(2):151-75
[PMID:
18188003]
Autophagy. 2008 Nov;4(8):1042-53
[PMID:
18927491]
Nat Rev Cancer. 2009 Oct;9(10):701-13
[PMID:
19693097]
Mol Cancer Ther. 2005 Apr;4(4):569-77
[PMID:
15827330]
Clin Cancer Res. 2010 Oct 1;16(19):4702-10
[PMID:
20858840]
J Biol Chem. 2009 Sep 25;284(39):26816-30
[PMID:
19648108]
Mol Cancer Ther. 2010 Jan;9(1):236-45
[PMID:
20053765]
Blood. 2010 Dec 16;116(25):5622-30
[PMID:
20844237]
Cell. 1997 Oct 31;91(3):325-34
[PMID:
9363941]
Breast Cancer Res. 2010;12 Suppl 2:S2
[PMID:
21050423]
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15077-82
[PMID:
14657337]
Nature. 1999 Dec 9;402(6762):672-6
[PMID:
10604474]
Breast Cancer Res. 2011 Jan 11;13(1):R3
[PMID:
21223569]
Int J Mol Med. 2000 Jun;5(6):597-604
[PMID:
10812007]
BMC Cancer. 2010 Dec 03;10:669
[PMID:
21129193]
Cancer Res. 2010 Oct 15;70(20):7970-80
[PMID:
20798217]
Cell. 2009 Apr 3;137(1):87-98
[PMID:
19345189]
Annu Rev Nutr. 2007;27:19-40
[PMID:
17311494]
Nature. 2007 Apr 12;446(7137):745-7
[PMID:
17429391]
Anticancer Res. 2009 Apr;29(4):1335-43
[PMID:
19414384]
Int J Biochem Cell Biol. 2004 Dec;36(12):2503-18
[PMID:
15325588]
Leuk Lymphoma. 2012 Oct;53(10):2024-32
[PMID:
22448923]
Oncogene. 2008 Oct 27;27(50):6522-37
[PMID:
18955977]
Antineoplastic Agents
Caspase Inhibitors
Cyclin-Dependent Kinase Inhibitor p21
Mutant Proteins
Oligopeptides
Receptors, Estrogen
Tumor Suppressor Protein p53
benzyloxycarbonyl-valyl-alanyl-aspartic acid
8-aminoadenosine
Adenosine
Doxycycline
